Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Emanuel, O; Liu, J; Schartinger, VH; Nei, WL; Chan, YY; Tsang, CM; Riechelmann, H; Masterson, L; Haybaeck, J; Oppermann, U; Willems, SM; Ooft, ML; Wollmann, G; Howard, D; Vanhaesebroeck, B; Lund, VJ; Royle, G; Chua, MLK; Lo, KW; Busson, P; Lechner, M.
SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target.
Cancers (Basel). 2021; 13(19):
Doi: 10.3390/cancers13194944
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Haybäck Johannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor, most commonly located in the pharyngeal recess and endemic to parts of Asia. It is often detected at a late stage which is associated with poor prognosis (5-year survival rate of 63%). Treatment for this malignancy relies predominantly on radiotherapy and/or systemic chemotherapy, which can be associated with significant morbidity and impaired quality of life. In endemic regions NPC is associated with infection by Epstein-Barr virus (EBV) which was shown to upregulate the somatostatin receptor 2 (SSTR2) cell surface receptor. With recent advances in molecular techniques allowing for an improved understanding of the molecular aetiology of this disease and its relation to SSTR2 expression, we provide a comprehensive and up-to-date overview of this disease and highlight the emergence of SSTR2 as a key tumor biomarker and promising target for imaging and therapy.
- Find related publications in this database (Keywords)
- nasopharyngeal carcinoma (NPC)
- somatostatin receptor 2 (SSTR)
- EBV
- epidemiology
- global health
- biomarkers
- carcinogenesis
- imaging
- therapeutics